A Stage 4 Breast Cancer Trial Came Close Enough to Home for Jamie Lynne Tarailo to Join
UC Davis' network access story shows how trial geography can decide whether a metastatic breast cancer patient can realistically participate.
- Published
- Jun 27, 2026
- Last updated
- Jun 27, 2026
- Last reviewed
- Jun 27, 2026
- Status
- Confirmed
- Primary source
- UC Davis Health
- Verification
- Primary / regulatory source
- Confidence
- very high
- Urgency
- high
Rapid orientation
The 5-second read
- What happened
- This is a clinical-trial access story, not a treatment outcome story.
- Why it matters
- Clinical trial access is often shaped by geography, transportation, work schedules, caregiver responsibilities, and referral networks.
- Status
- Confirmed
- Overclaim risk
- Medium high
- Primary source
- UC Davis Health (Official)
- Next thing to watch
- Whether UC Davis expands additional industry-sponsored trials into community sites and whether FourLight-3 reports tolerability or efficacy signals.
Signal context
Known so far
- Patient
- Jamie Lynne Tarailo
- Cancer subtype
- HR-positive, HER2-negative metastatic breast cancer
- Trial
- FourLight-3
- Access angle
- Trial delivered through a community cancer network
Claim Check
ConfirmedUC Davis said Jamie Lynne Tarailo enrolled in the first industry-sponsored clinical trial available through its Cancer Care Network.
Safe framing
This is a clinical-trial access story, not a treatment outcome story.
What happened
UC Davis profiled Jamie Lynne Tarailo, a nurse and mother with metastatic HR-positive, HER2-negative breast cancer who enrolled in a trial through the UC Davis Cancer Care Network.
The treatment being studied is not the whole story. The bigger VV angle is that the trial became physically reachable through a community-affiliated site, which can determine whether a patient can participate at all.
The clinical boundary is clear: this is not a reported response, remission, or survival outcome. It is an access milestone that shows why trial networks matter for people outside major academic centers.
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No miracle claims. Just better health signal.
By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.
Why it matters
- Clinical trial access is often shaped by geography, transportation, work schedules, caregiver responsibilities, and referral networks.
- Metastatic breast cancer patients may not have the time or energy to travel repeatedly to distant academic centers.
- This is a softer but important human breakthrough: trial infrastructure reaching the patient.
What not to overclaim
- Do not imply Jamie benefited clinically from the investigational therapy yet.
- Do not present FourLight-3 as superior to standard CDK4/6 inhibitor therapy before results.
- Do not turn an access story into a cure story.
Signal context
Context
- Primary topic
- Cancer Trial Access
- Source date
- Jun 26, 2026
- Source stack
- 2 sources
- Current status
- Confirmed
Evidence trail
Source stack
- PrimaryOfficialJun 26, 2026UC Davis Health: bringing cancer clinical trials close to home
- Journal / trialRegulatoryClinicalTrials.gov: trial registry search for FourLight-3 context
Keep following the signal
Related signal trail
Human Breakthrough Desk
Help us find and amplify more stories like this.
Some health stories should not vanish after one news cycle. Support the independent desk finding patient wins, medical breakthroughs, and human stories worth moving.
Support the Human Breakthrough Desk